Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Clinical trial NCT04889430 · COMPLETED

Trial details

NCT number: NCT04889430
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Atypical Hemolytic Uremic Syndrome

Start date: 2022-01-17
Primary completion: 2026-04-11
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.